first-party verification report 2026-08-25


medication-only pricing: $90 first month/$199 renewal + required membership $39 first month/$79 after; all-in $129 first month/$278 ongoing


medication-only $60 first/$99 renewal + membership $39 first/$79 after; all-in $99 first/$178 ongoing


PerfectRx/PerfectionRx; ProRx; Casa; Pharmacy Hub; SmartPharmaRx


503A (provider-stated; a separate page also says 503A/503B — inconsistency noted)


starter promotion ≈$149/mo-equivalent for two months; recurring $299


Tailor Made Compounding (Noom-acquired 503A operating in 46 states — corporate relationship, not universal patient assignment)


$129 first four weeks, then $249/mo billed quarterly; not available in all states


Tailor Made Compounding (corporate 503A relationship)


$149 first four weeks then $299/mo billed quarterly (GLP-1 Rx Plus)


includes shipping; active domain corrected from willow.health


all states except Hawaii (verified 2026-08-25)


lower monthly equivalents on 3-, 6-, 9-month commitments


first-time 3-month starter $375 total ($125/mo equivalent); recurring $597 quarterly ($199/mo) or $235 month-to-month


starter ≈$257/3-mo ($86 equiv); then $435 quarterly ($145) or $175 monthly


$149/mo equivalent on the long/prepaid annual plan, no dose-based increase; month-to-month not published


Emerald Compounding; Epiq Scripts; Southend; AbsoluteRx (disclosed partners; assignment varies)


$279 first month then $349 month-to-month; 3-mo $837 ($279 equiv); 6-mo $1,392 ($232 equiv); prior 12-month $229 plan not currently public


$179 is a 12-month-commitment equivalent, not month-to-month; 3-month plan ≈$209/mo


$125/mo on the annual plan, dose-inclusive; prior $235 month-to-month is outdated/not public


month-to-month, no commitment; active domain corrected from telepep.com


single month any dose $299; first-time starter $399/3-months ($133 equiv); other 12-week bundles $499–$599 by dose; prior $349 outdated


program ≈$199/mo, medication and labs excluded; brand out-of-pocket varies by insurance/savings eligibility


Zepbound single-dose vials: 2.5 mg $349/mo and 5 mg+ $499/mo, manufacturer-published self-pay list prices recorded by desk; first-party recheck queued


dose tiers: $299 (2.5 mg starter) / $399 (5 mg) / $449 (7.5–15 mg) under Self Pay Journey refill-timing conditions; regular $499 (7.5 mg) and $699 (10–15 mg) if conditions missed; card terms stated through 2026-12-31


Wegovy $199/mo at every dose, manufacturer-published cash price recorded by desk; first-party recheck queued


injection: $199/mo qualifying new-patient initial fills, then $349/mo ongoing self-pay


weekly injectable $297/mo (Program Offerings updated 2025-12-03); 6-mo $1,782 or $1,482 prepaid; 12-mo $3,564 or $2,364 prepaid; sublingual $249 and premium sublingual $179 are separate formats


oral tirzepatide only: $1,047/3-mo or $891 prepaid ($349 vs $297/mo equivalent); prior $179 month-to-month injectable record contradicted — $179 belongs to a different (premium sublingual semaglutide) offer


compounded tirzepatide from $199/mo when paid annually; the separate $149/mo card is a medication-EXCLUDED service for LillyDirect Zepbound access — prior 149/199 record combined two products and is contradicted


service membership $39 first month/$149 after with medications billed separately; current mix emphasizes FDA-approved brands incl. the Wegovy pill; legacy compounded offers ($165 annual) not supported by current pages


“from $99” is a starting claim, not a standard all-in recurring price; membership/program options from $49


$149 first month supported; current recurring renewal not found on an authoritative public checkout (legacy $359 unconfirmed)


current pricing page internally inconsistent: “as low as” $198/mo annual promo code, $240 annual elsewhere, and $359 vs $389 month-to-month in different markup — order agreement needed before promoting any figure


product page ≈$249 vs terms-of-service standard renewal ≈$199 after minimum term — conflict unresolved


product page ≈$349 vs terms ≈$299 standard renewal — conflict unresolved


Contigo Compounding (Eden-owned 503A, acquired 2025-08-19; other network pharmacies also referenced)


prior 249/329 not substantiated by a current authoritative checkout


Contigo Compounding (Eden-owned 503A; other partners referenced)


public pricing conflicts: $149 first/$249 after (Jan 2026 article) vs $99 medication + $39-then-$99 membership callouts — pending checkout capture


public per-state roster incl. AbsoluteRx/Nova, Alchemist, New Life Rx, Boudreaux, Empower, Hallandale, OptioRx, Red Rock, ReviveRx, Southend, South Lake, Strive, Vios


“from ≈$105” is a dose/pharmacy-dependent multi-month equivalent, not standard month-to-month; detailed tiers on treatment-plan-pricing page


public per-state roster (see tirzepatide row)


“from ≈$95” multi-month equivalent, dose/pharmacy-dependent


prepaid bundles only: $600/6-mo ($100 equiv), $499/4-mo (≈$124.75); membership $75/mo with first-month promo; standard month-to-month not published


$1,100/6-mo ($183 equiv) or $900/4-mo ($225); “starting at $133” is promotional-equivalent, not standard month-to-month


routine compounded semaglutide phased out following shortage changes; current model ≈$39 first month/$149-mo service with medication excluded, brand pathways emphasized


Zepbound cash tiers via Lilly offer: $299 (2.5 mg)/$399 (5 mg)/$449 (7.5–15 mg conditional); Ro Body membership separate ($39 first month, commitment-dependent after); Wegovy promo/dose-dependent


3-month starter $399 total ($133 equiv); ≈$299 4-week option shown elsewhere; higher-dose bundles separate


brand-medication program: WW Med+ membership separate (intro payment then commitment-dependent rates); brand self-pay advertised from ≈$199 offer-dependent; prior compounded-standard record not supported


“starting at $199” is intro-style; campaign terms indicate ≈$249 first month/$349 after — exact offer/checkout pending; previously identified pharmacies Foothills and Promise need recheck


campaign terms indicate ≈$199 first month/$299 after — pending capture


exact current price, state list, and dispensing pharmacy not publicly exposed


$199 verified as a starting price with no separate membership; not confirmed as the recurring price at all doses; states unresolved


current advertised flat monthly starting price incl. prescription and support


current advertised flat starting price; prior $239 record outdated/contradicted


long-plan lower bounds ≈$139 injectable and ≈$116 microdose; earlier $99/$69 figures were promotional and are contradicted as ongoing month-to-month prices; pharmacy name unknown, 503A provider-stated


quarterly page displays “$597 today” alongside “$185/mo” (3×$185=$555; $597÷3=$199) — arithmetic conflict flagged 2026-08-25; awaiting NexLife clarification whether the charge is $555, $597, or $185 plus separately disclosed fees